Cerdulatinib Dual-Kinase Inhibition for Resistant B-Cell Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for hematological malignancies, particularly B-cell lymphomas such as CLL, SLL, DLBCL, and FL, are limited, and patients often develop resistance to existing chemotherapeutic agents like ibrutinib and idelalisib due to mutations in BTK or downstream signaling proteins.
Innovation Solution
Administering cerdulatinib, a small molecule inhibitor of SYK and JAK family members, at doses ranging from 10 mg to 75 mg daily to patients with relapsed or refractory hematological cancers, including those with mutations linked to resistance or relapse, to target BCR and cytokine signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents like ibrutinib and idelalisib are used to treat B-cell malignancies, then disease suppression is achieved, but drug resistance develops due to mutations in BTK or downstream signaling proteins
Solution Approach 1:
The patent uses SYK as an intermediary target in the BCR signaling pathway. Instead of directly inhibiting BTK (which develops resistance), the invention targets SYK, an upstream kinase that mediates signals from the B-cell receptor. This intermediary approach allows inhibition of the signaling pathway before the resistance-causing mutations can effectively protect downstream components, thereby overcoming drug resistance while maintaining treatment efficacy.
2Ease of manufacture
If targeted kinase inhibitors are used to treat hematological malignancies, then specific signaling pathways are blocked, but treatment options become limited for relapsed or refractory patients
Solution Approach 1:
The patent employs a dual-inhibitor approach targeting both SYK and JAK family members with cerdulatinib. This multi-functional inhibition addresses multiple signaling pathways simultaneously (BCR signaling through SYK and cytokine signaling through JAKs), providing versatility in treating different types of hematological malignancies and overcoming the limitation of single-pathway targeted therapies, especially for relapsed or refractory cases.
Data Source
AI summary
Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof. The methods entail administering to the patient a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the patients suffer one or more of a B-cell malignancy, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or other transformed FL and/or have relapsed or not responded to a prior chemotherapy.